Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Acq. announced
Accel. buyback
Inv. presentation
Quarterly results
CC transcript
PFIZER INC (PFE) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/28/2022 8-K Quarterly results
05/03/2022 8-K Quarterly results
11/02/2021 8-K Quarterly results
Docs: "PFIZER REPORTS THIRD-QUARTER 2021 RESULTS"
07/28/2021 8-K Quarterly results
Docs: "PFIZER REPORTS SECOND-QUARTER 2021 RESULTS"
05/04/2021 8-K Quarterly results
10/27/2020 8-K Quarterly results
07/28/2020 8-K Quarterly results
04/28/2020 8-K Quarterly results
Docs: "PFIZER REPORTS FIRST-QUARTER 2020 RESULTS ▪ First-Quarter 2020 Revenues of $12.0 Billion, Reflecting 7% Operational Decline; Excluding the Impact from Consumer Healthcare , Revenues Declined 1% Operationally – 12% Operational Growth from Biopharma, Primarily Driven by Eliquis, Vyndaqel/Vyndamax, Ibrance and Inlyta as well as 15% Operational Growth in Emerging Markets – 37% Operational Decline from Upjohn, Primarily Due to U.S. Loss of Exclusivity of Lyrica in 2019 and Declines from Lipitor and Norvasc in China due to the Volume-Based Procurement Program ▪ First-Quarter 2020 Reported Diluted EPS of $0.61, Adjusted Diluted EPS of $0.80 ▪ Reaffirmed 2020 Financial Guidance for Revenues and Adjusted Diluted EPS , Absorbing Unfavorable Changes in Foreign Exchange Rates and Ref..."
10/29/2019 8-K Quarterly results
07/29/2019 8-K Quarterly results
04/30/2019 8-K Quarterly results
Docs: "PFIZER REPORTS FIRST-QUARTER 2019 RESULTS ▪ First-Quarter 2019 Revenues of $13.1 Billion, Reflecting 5% Operational Growth Driven by 7% Operational Growth from Pfizer Biopharmaceuticals Group and 1% Operational Growth From Upjohn ▪ First-Quarter 2019 Reported Diluted EPS of $0.68, Adjusted Diluted EPS of $0.85 ▪ Raised Midpoint of 2019 Adjusted Diluted EPS Guidance Range by $0.01 to $2.83 to $2.93, Primarily Reflecting Adjusted Other Income Recorded During First-Quarter 2019, Partially Offset by the Unfavorable Impact of Foreign Exchange ▪ Reaffirmed 2019 Financial Guidance for Revenues"
10/30/2018 8-K Quarterly results
07/31/2018 8-K Quarterly results
10/31/2017 8-K Quarterly results
08/01/2017 8-K Quarterly results
11/01/2016 8-K Form 8-K - Current report
08/02/2016 8-K Form 8-K - Current report
05/03/2016 8-K Form 8-K - Current report
10/27/2015 8-K Quarterly results
07/28/2015 8-K Quarterly results
04/28/2015 8-K Quarterly results
Docs: "PFIZER REPORTS FIRST-QUARTER 2015 RESULTS ▪ First-Quarter 2015 Reported Revenues of $10.9 Billion ▪ First-Quarter 2015 Adjusted Diluted EPS of $0.51, Reported Diluted EPS of $0.38; Both Adjusted Diluted EPS and Reported Diluted EPS Include a $0.03 Negative Impact Associated with an Upfront Payment to OPKO Health, Inc. ▪ Repurchased $6.0 Billion of Common Stock in First-Quarter 2015, Including a $5.0 Billion Accelerated Share Repurchase Agreement Executed in February ▪ Updated Certain Components of 2015 Financial Guidance Solely to Reflect the Negative Impact of Recent Changes in Foreign Exchange Rates"
10/28/2014 8-K Quarterly results
07/29/2014 8-K Quarterly results
05/05/2014 8-K Quarterly results
Docs: "EXHIBIT"
10/29/2013 8-K Form 8-K - Current report
07/30/2013 8-K Form 8-K - Current report
04/30/2013 8-K Quarterly results
Docs: "PFIZER REPORTS FIRST-QUARTER 2013 RESULTS"
11/01/2012 8-K Form 8-K - Current report
07/31/2012 8-K Form 8-K - Current report
05/01/2012 8-K Form 8-K - Current report
11/01/2011 8-K Form 8-K - Current report
08/02/2011 8-K Form 8-K - Current report
05/03/2011 8-K Form 8-K - Current report
02/01/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy